1. Home
  2. SIBN vs RLMD Comparison

SIBN vs RLMD Comparison

Compare SIBN & RLMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo SI-BONE Inc.

SIBN

SI-BONE Inc.

HOLD

Current Price

$15.39

Market Cap

641.3M

Sector

Health Care

ML Signal

HOLD

Logo Relmada Therapeutics Inc.

RLMD

Relmada Therapeutics Inc.

HOLD

Current Price

$6.42

Market Cap

661.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SIBN
RLMD
Founded
2008
2004
Country
United States
United States
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
641.3M
661.9M
IPO Year
2018
2012

Fundamental Metrics

Financial Performance
Metric
SIBN
RLMD
Price
$15.39
$6.42
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
8
5
Target Price
$23.88
$12.40
AVG Volume (30 Days)
488.9K
1.0M
Earning Date
05-11-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
41.33
45.28
EPS
N/A
N/A
Revenue
$67,301,000.00
$13,070.00
Revenue This Year
$16.95
N/A
Revenue Next Year
$14.93
N/A
P/E Ratio
N/A
N/A
Revenue Growth
21.53
154.83
52 Week Low
$11.48
$0.52
52 Week High
$21.89
$8.00

Technical Indicators

Market Signals
Indicator
SIBN
RLMD
Relative Strength Index (RSI) 62.79 44.94
Support Level $14.62 $6.17
Resistance Level $15.98 $7.46
Average True Range (ATR) 0.62 0.38
MACD 0.10 -0.09
Stochastic Oscillator 85.28 43.55

Price Performance

Historical Comparison
SIBN
RLMD

About SIBN SI-BONE Inc.

SI-BONE Inc is a medical device company that develops and commercializes a proprietary minimally invasive surgical implant system in the United States and internationally. Its products include a series of patented titanium implants and the instruments used to implant them, as well as implantable bone products such as iFuse-3D, iFuse-TORQ, and iFuse Bedrock Granite, which have applications across sacroiliac joint dysfunction and fusion, adult spinal deformity and degeneration, and pelvic trauma.

About RLMD Relmada Therapeutics Inc.

Relmada Therapeutics Inc is a clinical-stage, publicly traded biotechnology company focused on the development of NDV-01 and sepranolone. NDV-01 is a novel, controlled-release intravesical formulation of gemcitabine and docetaxel. NDV-01 is currently in a Phase 2 clinical trial in Isreal to assess its safety and efficacy in patients with aggressive forms of non-muscle invasive bladder cancer (NMIBC). Sepranolone is a novel neurosteroid epimer of allopregnanolone. sepranolone is being developed for the potential treatment of Prader-Willi Syndrome, Tourette Syndrome, excessive tremor and other diseases related to excessive GABAergic activity.

Share on Social Networks: